US OptionsDetailed Quotes
SLNO250516C110000
- 0.00
- 0.000.00%
15min DelayClose Apr 28 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest110.00Strike Price0.00Turnover0.00%IV49.38%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma35.92Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Soleno Therapeutics Stock Discussion
Breakthrough PWS Treatment VYKAT XR Now Available: First-Ever FDA Approval for Rare Disease
🌊 Riding the Waves of Market Turbulence
Last week's top performer achieved a staggering 59.33% return! How's that for paper profits in these cho...
Plunges? Rebounds? Hesitant in the volatile market? Try your strategy in paper trading first! The competition enters into its last week, Click here sign up now for up to US$500 stock cash coupons>>
👏Congratulations to the top 10 mooers on the leaderboard!
@Warren Buffed @102611933 @Jon93 @101693981 @redevilgiggs @Buffettwannabe @StephenKing9900 @随风飘逸 @凌波X微步 @叫我第一名
*Data from 21:30 SGT, March 31, 2025 ~ 4:00 SGT...
Gapping Up
Shares of $Soleno Therapeutics (SLNO.US)$ surged 36.6% following the U.S. FDA's approval of VYKATTM XR for the treatment of hyperphagia in Prader-Willi Syndrome, as announced by Soleno Therapeutics.
$KE Holdings (BEKE.US)$ shares rose 3.8% following the news that its subsidiary, Beihaojia, has expanded into Changsha for the first time.
$Liberty Energy (LBRT.US)$'s shares increased by 2.9% after Morgan Stanley...
https://snsim.moomoo.com/share/server/soakc?lang=en-us
No comment yet